Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Executive Summary

Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.

Advertisement

Related Content

Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Pfizer/Celltrion Prep For October Inflectra Launch
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel